Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P953: ROLE OF THE COMBINATION...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P953: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING NEWLY DIAGNOSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE TRIAL

P953: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING NEWLY DIAGNOSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE TRIAL

Bibliographic Details
Main Authors: Claudio Cerchione, Davide Nappi, Matteo Marchesini, Giacomo Feliciani, Andrea Prochowski Iamurri, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Claudia Matuozzo, Fabiana Mammoli, Federica Frabetti, Giovanni Paganelli, Federica Matteucci, Caterina Pallotti, Emanuela Scarpi, Chiara Pazzi, Domenico Barone, Antonino Romeo, Giorgia Simonetti, Gerardo Musuraca, Giovanni Martinelli, Alice Rossi
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000970716.33151.14
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000970716.33151.14

Similar Items

  • P918: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL
    by: Claudio Cerchione, et al.
    Published: (2023-08-01)
  • PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS’ ERA
    by: C. Cerchione, et al.
    Published: (2022-06-01)
  • PB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET
    by: C. Cerchione, et al.
    Published: (2022-06-01)
  • PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE
    by: C. Cerchione, et al.
    Published: (2022-06-01)
  • PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
    by: C. Cerchione, et al.
    Published: (2022-06-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs